⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880198 | 1.00 | — | — | |
| SCHEMBL3851698 | 1.00 | — | — | |
| SCHEMBL4482087 | 1.00 | — | — | |
| SCHEMBL3877473 | 1.00 | — | — | |
| SCHEMBL13896863 | 1.00 | — | — | |
| SCHEMBL13817400 | 1.00 | — | — | |
| SCHEMBL565889 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3875303 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15817550 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20699876 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| WO-2025202991-A1 | CRYSTALLINE FORM OF (S)-N-ETHYL-3-((9-ETHYL-2-(((2R,3S)-2-HYDROXYPENTAN-3-YL)AMINO)-9H-PURIN-6-YL)AMINO)-PYRROLIDINE-1-SULFONAMIDE | ASTRAZENECA AB (SE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| CN-119462661-A | Preparation method of AZD-8421 and intermediate thereof | 烟台皓元生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118598874-A | Substituted 9H purine compound, pharmaceutical composition and application thereof | 江南大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4212533-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | Cyclacel Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212533-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | Cyclacel Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |